South Korea's Enzychem To Make Cadila's COVID-19 Shot

Cadila will get license fees and royalty payments, the company said in a filing (Representational)
South Korea’s Enzychem Lifesciences would make at least 80 million doses of India’s homegrown DNA COVID-19 vaccine from Cadila Healthcare, the domestic drugmaker said on Wednesday.
As part of the deal, Cadila will transfer the DNA vaccine technology to Enzychem, which will make and sell the vaccine, ZyCoV-D, within its territory under the Cadila trademark. Cadila will get license fees and royalty payments, the company said in a filing to stock exchanges.
“(The DNA) technology allows vaccines to be produced at affordable costs in record times, and DNA vaccines are considerably stable,” said Ki Young Sohn, chairman of Enzychem Lifesciences.
“ZyCoV-D is administered without needles and can be deployed more readily, especially in resource-poor populations.”

Cadila’s vaccine, which is administered in three doses, was approved by the country’s drug regulator in August for emergency use in adults and children aged 12 years and above, though it has yet to be rolled out as part of the county’s vaccination drive.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Track Latest News Live on and get news updates from India and around the world.
Watch Live News:
Follow Us:
………………………….. Advertisement …………………………..



Leave a Reply

Your email address will not be published. Required fields are marked *

forty two  ⁄  7  =  

Next Post

Australia Nanny Accused Of Pinochet-Era Crimes Loses Extradition Appeal

Thu Nov 25 , 2021
Adriana Elcira Rivas Gonzalez has lived in Australia for three decades.An Australia-based former nanny lost her second appeal against extradition to Chile on Wednesday where she allegedly served as a member of the feared secret police during the dictatorship of Augusto Pinochet.Adriana Elcira Rivas Gonzalez, now in her late 60s, […]